Compare WSM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSM | ILMN |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.0B |
| IPO Year | 1995 | 2000 |
| Metric | WSM | ILMN |
|---|---|---|
| Price | $175.28 | $117.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | ★ $209.71 | $124.24 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 03-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 0.57 | ★ 170.87 |
| EPS | ★ 8.84 | 5.45 |
| Revenue | ★ $7,806,816,000.00 | $4,343,000,000.00 |
| Revenue This Year | $5.37 | $6.54 |
| Revenue Next Year | $4.13 | $5.49 |
| P/E Ratio | ★ $20.42 | $22.84 |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $130.07 | $68.70 |
| 52 Week High | $221.81 | $155.53 |
| Indicator | WSM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 38.77 |
| Support Level | $161.76 | $115.02 |
| Resistance Level | $175.68 | $135.68 |
| Average True Range (ATR) | 6.95 | 4.66 |
| MACD | -0.11 | 0.19 |
| Stochastic Oscillator | 3.40 | 13.18 |
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the nearly $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (152 stores) offers high-end cooking essentials, while Pottery Barn (183) provides casual home accessories. West Elm (120) is an emerging concept for young professionals, and Rejuvenation (13) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (45) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.